

LONDON NOTICE No. 2667

ISSUE DATE: 20 July 2005
EFFECTIVE DATE: 1 August 2005

OPTION CONTRACT ON EQUITY SHARES (DENOMINATED IN STERLING) (EXCHANGE CONTRACT NO. 201)

CHANGE TO EXCHANGE TRANSACTION FEES FOR ASTRAZENECA PLC INDIVIDUAL EQUITY OPTION CONTRACT

Executive Summary

This Notice informs members of a change to the Exchange transaction fees in respect of the AstraZeneca plc Individual Equity Option Contract.

1. General Notice No. 2281, issued on 12 September 2003, informed members of a change to the standard contract size of the AstraZeneca plc Individual Equity Option Contract (“the Contract”). General Notice No. 2281 also advised members that, until further notice, the Exchange transaction fee of 10 pence per side, per lot would remain for all 100 share and 1,000 share expiry months in the Contract.
2. This Notice informs members that, given all expiry months in the Contract now have a standard contract size of 1,000 shares per lot, on and from 1 August 2005 the Exchange transaction fees for the Contract will revert to the standard 37 pence per side, per lot for options traded via the Central Order Book and Block Trade Facility and 35 pence per side, per lot for those that are reported through the OTC Facility.

For further information in relation to this Notice, please contact:

Caterina Caramaschi +44 (0) 20 7379 2785 caterina.caramaschi@liffe.com

Web site: www.euronext.com/derivatives

The Euronext Derivatives Markets ("Euronext.liffe") include the markets for derivatives operated by Euronext Amsterdam, Euronext Brussels, Euronext Lisbon, Euronext Paris and LIFFE Administration and Management, referred to respectively as the Amsterdam, Brussels, Lisbon, Paris and London markets.

Euronext NV, PO Box 19163, 1000 GD Amsterdam, The Netherlands